Ganirelix Acetate API (CAS 123246-29-7) | 99% Peptide Supply
Ganirelix Acetate API,CAS 123246-29-7,Synthetic Decapeptide,GnRH Antagonist API,Solid-Phase Peptide Synthesis,IVF formulation raw material,wholesale peptide manufacturer,Shaanxi Sunrise
Content
⚠ STRICT REGULATORY DIRECTIVE: B2B INDUSTRIAL RAW MATERIALS ONLY
This operational facility strictly functions as a primary industrial manufacturer and supplier of active pharmaceutical ingredients (APIs) and biochemical raw materials. We do not engage in the production or distribution of finished retail pharmaceutical dosage forms. The technical dossier below regarding Ganirelix Acetate (CAS No. 123246-29-7) is published exclusively for advanced reproductive research, formulation engineering, and bulk pharmaceutical manufacturing procurement.
Is Your Ganirelix Acetate Sourcing Compromising IVF Clinical Outcomes?
The Hidden Risks in Peptide Formulation Sourcing
In the highly regulated arena of Assisted Reproductive Technology (ART) and controlled ovarian stimulation (COS), formulation engineers face an unforgiving benchmark: absolute molecular precision. Ganirelix Acetate (CAS 123246-29-7) operates as a potent, third-generation synthetic GnRH antagonist. However, the commercial procurement of this decapeptide is currently plagued by a critical industry blind spot—substandard peptide synthesis resulting in truncated sequences and residual cleavage solvents.
When pharmaceutical brands source generic peptide materials from unverified brokers rather than primary API manufacturers, they inadvertently introduce structural impurities that directly interfere with receptor binding kinetics. By executing stringent Solid-Phase Peptide Synthesis (SPPS) and rigorous chromatographic isolation internally, we supply Ganirelix Acetate API with a guaranteed purity of ≥ 99.0%. This technical whitepaper dissects why SPPS accuracy and strict cold-chain compliance are non-negotiable for modern reproductive drug development.
Why Are Truncated Sequences a Critical Threat to ART Efficacy?
Synthesizing a decapeptide like Ganirelix involves a highly complex sequence of coupling and deprotection reactions. During standard Solid-Phase Peptide Synthesis (SPPS), failure to drive chemical couplings to 100% completion inevitably generates truncated peptides (missing one or more amino acid residues) or deletion sequences.
For formulation scientists, these impurities are a catastrophic liability. Because truncated peptides share highly similar isoelectric points and hydrophobicity with the target Ganirelix molecule, they frequently bypass basic downstream purification filters. Once formulated into an injectable aqueous solution, these structurally similar contaminants competitively bind to GnRH receptors in the pituitary gland, drastically diluting the therapeutic suppression of Luteinizing Hormone (LH). Procuring API from our strictly audited facility eliminates this variable, ensuring your final dosage form delivers predictable, uncompromised biological activity.
The Pharmacological Mandate: Immediate GnRH Antagonism
The clinical superiority of Ganirelix over first-generation GnRH agonists lies in its mechanism of action. Agonists inherently trigger an initial "flare-up" effect—a massive release of gonadotropins before receptor downregulation occurs. This requires a prolonged, multi-week desensitization phase, causing patient discomfort and increasing the risk of Ovarian Hyperstimulation Syndrome (OHSS).
In contrast, pure Ganirelix Acetate functions as a direct competitive antagonist. It instantly blocks endogenous GnRH from binding to pituitary receptors, inducing an immediate, dose-dependent suppression of the LH surge. This precise mechanism prevents premature follicle rupture and allows for highly synchronized oocyte maturation during in vitro fertilization (IVF) cycles. To achieve this immediate pharmacokinetic response, the starting API substrate must possess exceptional structural integrity, free from isomeric interference.
Technical Specification Matrix (API Release Standards)
Protect your regulatory submissions and formulation baselines by strictly auditing your peptide procurement. Review our audited release specifications for Ganirelix Acetate below:
| Analytical Parameter | Factory Release Specification |
|---|---|
| Product Identifier | Ganirelix Acetate (Synthetic Decapeptide) |
| CAS Registry Number | 123246-29-7 |
| Chromatographic Purity | HPLC ≥ 99.0% |
| Molecular Formula | C80H113N18O13 · 2C2H4O2 |
| Molecular Weight | 1690.4 Da |
| Physical Appearance | White to off-white highly hygroscopic lyophilized powder |
| Identity Verification | Confirmed via High-Resolution Mass Spectrometry (MS) |
| Acetate Content | Strictly controlled to pharmaceutical formulation requirements |
Procurement FAQ: Managing Cold-Chain & API Formulation
How do you manage the strict -20°C storage requirement during transoceanic shipping?
Peptide degradation via hydrolysis is a severe risk if temperature and moisture controls fail during transit. We deploy validated, medical-grade cold-chain logistics for all international shipments. The lyophilized Ganirelix powder is vacuum-sealed inside sterile, moisture-barrier aluminum foil pouches, which are then packed into heavy-duty insulated EPS containers loaded with regulated dry ice to maintain constant sub-zero stability.
Can this material be utilized directly for liposomal or novel sustained-release ART formulations?
Yes. Because our SPPS purification removes excessive residual trifluoroacetic acid (TFA) and controls the specific acetate counterion ratios, the resulting API powder demonstrates excellent solubility and stability profiles in aqueous vehicles, making it an ideal candidate for both standard subcutaneous injections and advanced microsphere or liposomal encapsulation technologies.
Is comprehensive regulatory paperwork provided for facility audits?
Absolutely. Every commercial batch is dispatched with a full Certificate of Analysis (COA) containing the exact HPLC chromatogram and MS spectra. We operate under stringent manufacturing guidelines, ensuring all heavy metal, endotoxin, and residual solvent limits comply fully with international pharmacopeia standards.
Do you accommodate custom milligram-scale aliquots for university or early-stage R&D?
Yes. We actively support reproductive research institutions. Beyond bulk commercial scaling, we provide highly precise, sterile-packed aliquots (ranging from 10mg to 500mg) designed specifically to facilitate dissolution trials, pre-clinical pharmacokinetic mapping, and formulation prototyping without forcing massive MOQs.